Get started
Author

Sarah K. Knutson

Observed names: S. K. Knutson, S. Knutson, Sarah K Knutson, Sarah Knutson
ORCID: 0009-0007-2676-8607
Observed ORCID: 0009-0007-2676-8607
OpenAlex ID: A5038902590
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
2013 · Sarah K. Knutson, Natalie M. Warholic, et al. · Proceedings of the National Academy of Sciences · 810
PDF
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
2012 · Sarah K Knutson, Tim J Wigle, et al. · Nature Chemical Biology · 791
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
2010 · Christopher J. Sneeringer, Margaret Porter Scott, et al. · Proceedings of the National Academy of Sciences · 719
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma
2014 · Sarah K. Knutson, Satoshi Kawano, et al. · Molecular Cancer Therapeutics · 547
Loss of BAP1 function leads to EZH2-dependent transformation
2015 · Lindsay M LaFave, Wendy Béguelin, et al. · Nature Medicine · 392
Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control
2008 · Srividya Bhaskara, Brenda J. Chyla, et al. · Molecular Cell · 375
PDF
Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability
2010 · Srividya Bhaskara, Sarah K. Knutson, et al. · Cancer Cell · 363
PDF
Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
2008 · Sarah K Knutson, Brenda J Chyla, et al. · The EMBO Journal · 272
PDF
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
2016 · Kevin W. Kuntz, John E. Campbell, et al. · Journal of Medicinal Chemistry · 186
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
2017 · Elayne Chan-Penebre, Kelli Armstrong, et al. · Molecular Cancer Therapeutics · 175
A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients
2012 · Christina R. Majer, Lei Jin, et al. · FEBS Letters · 154
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
2015 · John E. Campbell, Kevin W. Kuntz, et al. · ACS Medicinal Chemistry Letters · 131
Histone Deacetylase 3 Depletion in Osteo/Chondroprogenitor Cells Decreases Bone Density and Increases Marrow Fat
2010 · David F. Razidlo, Tiffany J. Whitney, et al. · PLoS ONE · 113
PDF
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
2011 · Tim J. Wigle, Sarah K. Knutson, et al. · FEBS Letters · 94
PDF
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
2017 · Dorothy Brach, Danielle Johnston-Blackwell, et al. · Molecular Cancer Therapeutics · 77
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
2016 · Satoshi Kawano, Alexandra R. Grassian, et al. · PLoS ONE · 74
PDF
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
2014 · Sarah K. Knutson, Natalie M. Warholic, et al. · PLoS ONE · 71
PDF
Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2
2014 · Brooke M. Swalm, Sarah K. Knutson, et al. · ACS Chemical Biology · 35
Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins
2024 · Meng-Hsiung Hsieh, Yonglong Wei, et al. · Journal of Clinical Investigation · 14
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"
2016 · Lindsay M LaFave, Wendy Béguelin, et al. · Nature Medicine · 10
A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality
2015 · A. R. Grassian, T. M. E. Scales, et al. · Biological Procedures Online · 6
PDF
EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models
2013 · L. Danielle Johnston, Sarah Knutson, et al. · Blood · 5
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
2024 · Robinson Triboulet, Khikmet Sadykov, et al. · Molecular Cancer Therapeutics · 4
Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice
2012 · Heike Keilhack, Akira Yokoi, et al. · Blood · 4
Proceedings of the inaugural Dark Genome Symposium: November 2022
2023 · Jef D. Boeke, Kathleen H. Burns, et al. · Mobile DNA · 3
PDF
Works count: 55
Citation count: 5,435
H-index: 18
I10-index: 20
Year
Topic
Type